| Terminated | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced N Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV | Phase 3 | 2013-04-01 |
| Completed | An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cance Breast Cancer, HER-2 Positive Breast Cancer, Triple Negative Breast Cancer | Phase 2 | 2012-07-01 |
| Completed | A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) Non Small Cell Lung Cancer | Phase 2 | 2012-04-01 |
| Terminated | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic | Phase 2 / Phase 3 | 2011-05-01 |
| Unknown | Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 1 | 2011-01-01 |
| Completed | A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors Solid Tumor Malignancies | Phase 1 | 2010-07-01 |
| Completed | A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GI Gastrointestinal Stromal Tumor | Phase 2 | 2010-01-01 |
| Completed | A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) Non Small Cell Lung Cancer | Phase 2 | 2009-11-01 |
| Completed | A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Blast-phase Chronic Myelogenous Leukemia | Phase 1 | 2009-08-01 |
| Completed | STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders AML, CML, MDS | Phase 1 | 2009-03-01 |
| Suspended | A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors Metastatic Solid Tumors | Phase 1 | 2009-01-01 |
| Completed | A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prostate Cancer | Phase 1 | 2008-11-01 |
| Completed | Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors Solid Tumors | Phase 1 | 2007-10-01 |
| Unknown | Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors Solid Tumors | Phase 1 | 2007-10-01 |
| Terminated | Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma Melanoma | Phase 3 | 2007-08-01 |
| Completed | A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylat Active, Moderate to Severe Rheumatoid Arthritis | Phase 2 | 2005-12-01 |
| Completed | Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease Crohn's Disease | Phase 2 | 2005-11-01 |
| Completed | Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease Crohn's Disease | Phase 2 | 2005-08-01 |
| Completed | A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas Soft Tissue Sarcoma | Phase 2 | 2004-07-01 |
| Completed | A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors Advanced or Metastatic Solid Tumors | Phase 1 | 2004-06-01 |
| Completed | STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma Melanoma | Phase 1 / Phase 2 | 2004-05-01 |
| Completed | STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | 2004-03-01 |
| Completed | STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Pati Hematological Malignancies, Leukemia, Lymphoma | Phase 1 | 2004-02-01 |
| Completed | STA-5326 in Crohn's Disease Patients Crohn's Disease | Phase 1 / Phase 2 | 2004-02-01 |
| Completed | STA-4783 and Paclitaxel for Treatment of Solid Tumors Neoplasms | Phase 1 | 2003-01-01 |